SG11202000025SA - Improved dual specificity polypeptide molecule - Google Patents
Improved dual specificity polypeptide moleculeInfo
- Publication number
- SG11202000025SA SG11202000025SA SG11202000025SA SG11202000025SA SG11202000025SA SG 11202000025S A SG11202000025S A SG 11202000025SA SG 11202000025S A SG11202000025S A SG 11202000025SA SG 11202000025S A SG11202000025S A SG 11202000025SA SG 11202000025S A SG11202000025S A SG 11202000025SA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptide molecule
- dual specificity
- improved dual
- specificity polypeptide
- improved
- Prior art date
Links
- 230000009977 dual effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532713P | 2017-07-14 | 2017-07-14 | |
| DE102017115966.5A DE102017115966A1 (de) | 2017-07-14 | 2017-07-14 | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| DE102017119866 | 2017-08-30 | ||
| US201862658318P | 2018-04-16 | 2018-04-16 | |
| DE102018108995 | 2018-04-16 | ||
| PCT/EP2018/069151 WO2019012138A1 (fr) | 2017-07-14 | 2018-07-13 | Molécule polypeptidique à double spécificité améliorée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000025SA true SG11202000025SA (en) | 2020-02-27 |
Family
ID=62951983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000025SA SG11202000025SA (en) | 2017-07-14 | 2018-07-13 | Improved dual specificity polypeptide molecule |
| SG11202000027WA SG11202000027WA (en) | 2017-07-14 | 2018-07-13 | Improved dual specificity polypeptide molecule |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000027WA SG11202000027WA (en) | 2017-07-14 | 2018-07-13 | Improved dual specificity polypeptide molecule |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US20190016802A1 (fr) |
| EP (3) | EP3985029A1 (fr) |
| JP (4) | JP2020530762A (fr) |
| KR (2) | KR20200026994A (fr) |
| CN (2) | CN110914308A (fr) |
| AU (2) | AU2018298884A1 (fr) |
| BR (2) | BR112020000762A2 (fr) |
| CA (2) | CA3069610A1 (fr) |
| CO (2) | CO2020001029A2 (fr) |
| CR (2) | CR20200013A (fr) |
| CY (2) | CY1124091T1 (fr) |
| DK (2) | DK3428194T3 (fr) |
| ES (2) | ES2871146T3 (fr) |
| HR (1) | HRP20211744T1 (fr) |
| HU (2) | HUE057110T2 (fr) |
| LT (2) | LT3428194T (fr) |
| MA (1) | MA46299B1 (fr) |
| MD (2) | MD3428194T2 (fr) |
| MX (1) | MX2020011744A (fr) |
| PE (2) | PE20200614A1 (fr) |
| PL (2) | PL3652215T3 (fr) |
| PT (2) | PT3652215T (fr) |
| RS (2) | RS62544B1 (fr) |
| SG (2) | SG11202000025SA (fr) |
| SI (2) | SI3652215T1 (fr) |
| TW (2) | TWI817302B (fr) |
| WO (2) | WO2019012138A1 (fr) |
| ZA (1) | ZA202000842B (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3428194T3 (da) | 2017-07-14 | 2021-11-15 | Immatics Biotechnologies Gmbh | Forbedret polypeptidmolekyle med dobbelt specificitet |
| CN112424230A (zh) | 2018-05-14 | 2021-02-26 | 英美偌科有限公司 | 双功能结合多肽 |
| GB201904328D0 (en) | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| AU2020283500A1 (en) | 2019-05-27 | 2022-01-27 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| WO2021113748A1 (fr) * | 2019-12-05 | 2021-06-10 | Arbele Corp. | Composition d'anticorps triaxiaux et son procédé de production et d'utilisation |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| GB202006629D0 (en) | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| GB202010329D0 (en) | 2020-07-06 | 2020-08-19 | Immunocore Ltd | Specific binding molecules |
| WO2022040631A1 (fr) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Procédés d'isolement de lymphocytes t sélectionnés cd8+ |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| WO2022184805A1 (fr) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Protéines de liaison à l'antigène se liant spécifiquement à des peptides antigéniques du sars-cov-2 en un complexe avec une protéine du complexe majeur d'histocompatibilité |
| EP4334361A1 (fr) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Protéines de liaison à l'antigène se liant de manière spécifique à prame |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| EP4113120A1 (fr) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Procédé de caractérisation des caractéristiques de liaison entre un peptide d'intérêt et des molécules du cmh |
| CN117964777A (zh) * | 2021-08-26 | 2024-05-03 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| US20230190807A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Tcr compounds, compositions, and methods of treating |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| WO2023081461A1 (fr) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Procédés de génération de sphéroïdes cellulaires |
| CA3240046A1 (fr) * | 2021-12-14 | 2023-06-22 | Cdr-Life Ag | Activateur double de lymphocytes t ciblant le cmh |
| WO2023156663A1 (fr) | 2022-02-20 | 2023-08-24 | Immunocore Limited | Molécules de liaison spécifiques au vih et tcr |
| WO2023212697A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation |
| WO2023212691A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Polypeptides récepteurs de tgfβ négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation |
| WO2023212655A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation |
| WO2023209124A1 (fr) | 2022-04-29 | 2023-11-02 | Immatics Biotechnologies Gmbh | Plateforme d'exposition sur cellules de mammifère pour protéines de liaison à l'antigène multispécifiques |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2023240124A1 (fr) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Particules virales pseudotypées pour le ciblage de cellules exprimant un tcr |
| WO2024033332A1 (fr) | 2022-08-08 | 2024-02-15 | Immatics Biotechnologies Gmbh | Procédé de balayage de position guidé |
| WO2024130179A1 (fr) | 2022-12-16 | 2024-06-20 | Repertoire Immune Medicines, Inc. | Récepteurs de lymphocytes t se liant à des épitopes de hpv-16 |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (fr) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Anticorps monoclonaux contre le recepteur alpha-beta de cellules t humaines, leur production et leur utilisation |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| ATE434040T1 (de) | 2001-10-01 | 2009-07-15 | Dyax Corp | Mehrkettige eukaryontische display-vektoren und deren verwendungen |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| LT2275441T (lt) | 2005-04-01 | 2016-12-12 | Immunocore Ltd. | Dideliu afiniškumu pasižymintys živ t ląstelių receptoriai |
| ES2707152T3 (es) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| CA2609142C (fr) | 2005-05-27 | 2016-02-09 | Fondazione Centro San Raffaele Del Monte Tabor | Vecteurs geniques therapeutiques comprenant des sequences cibles de microarn |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| WO2008045437A2 (fr) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | RÉCEPTEURS CHIMÉRIQUES DES CELLULES T ET CELLULES T CIBLANT LE EGFRvIII SUR DES TUMEURS |
| WO2008145139A1 (fr) | 2007-05-31 | 2008-12-04 | Genmab A/S | Protéines de fusion ou liéee à demi-vie étendue |
| US20100317546A1 (en) | 2008-01-11 | 2010-12-16 | Morphosys Ag | Display Vectors and Methods and Uses Thereof |
| EP2258719A1 (fr) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Récepteur de lymphocyte T à cibles multiples |
| WO2011041093A1 (fr) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Récepteurs d'antigènes chimériques anti-récepteur 2 du facteur de croissance de l'endothélium vasculaire, et leur utilisation pour le traitement du cancer |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| WO2011085178A1 (fr) | 2010-01-11 | 2011-07-14 | Trustees Of Dartmouth College | Protéine de fusion monomérique bispécifique |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| JP6278598B2 (ja) | 2010-11-30 | 2018-02-14 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
| KR101944557B1 (ko) | 2011-02-11 | 2019-01-30 | 메모리얼 슬로안 케터링 캔서 센터 | 에이치엘에이 제한된, 펩타이드특이성 항원 결합 단백질 |
| US20130078250A1 (en) * | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| CA2887486A1 (fr) | 2012-11-30 | 2014-06-05 | Roche Glycart Ag | Elimination de cellules cancereuses en faisant circuler des lymphocytes t cytotoxiques specifiques d'un virus a l'aide de molecules de cmh de classe i ciblees sur les cellules cancereuses comprenant des proteines multifonctionnelles |
| NZ708182A (en) | 2013-02-26 | 2019-08-30 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| CN104936985A (zh) | 2013-02-26 | 2015-09-23 | 罗切格利卡特公司 | 双特异性t细胞活化性抗原结合分子 |
| RU2020115527A (ru) * | 2013-03-14 | 2020-07-07 | Макродженикс, Инк. | Биспецифичные молекулы, иммунореактивные с иммунными эффекторными клетками, экспрессирующими активирующий рецептор |
| AU2014357292B2 (en) | 2013-11-27 | 2020-06-25 | Zymeworks Bc Inc. | Bispecific antigen-binding constructs targeting HER2 |
| PT3083689T (pt) | 2013-12-17 | 2020-08-27 | Genentech Inc | Anticorpos anti-cd3 e métodos de utilização |
| DK3488862T3 (da) | 2014-03-25 | 2022-08-01 | Boehringer Ingelheim Animal Health Usa Inc | Immunologiske sammensætninger indeholdende svækket histophilus somni |
| AU2015292590B2 (en) | 2014-07-24 | 2020-01-16 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
| CA2958200A1 (fr) | 2014-08-14 | 2016-02-18 | Novartis Ag | Traitement du cancer a l'aide du recepteur d'antigene chimerique gfr alpha-4 |
| EP2985294A1 (fr) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Molécule d'anticorps de recombinaison et son utilisation pour l'activation des lymphocytes T restreints de cellule cible |
| BR112017007086A2 (pt) * | 2014-11-20 | 2018-01-16 | Hoffmann La Roche | moléculas de ligação, anticorpo biespecífico, variante de afinidade de uma molécula de ligação, polipeptídeos isolados, polinucleotídeos isolados, vetor, célula hospedeira, método para produzir a molécula de ligação, composição farmacêutica, uso da molécula de ligação, métodos de tratamento de uma doença e para induzir a lise de uma célula |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| US10744157B2 (en) | 2015-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| CA2986254A1 (fr) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions et methodes de reprogrammation de tcr au moyen de proteines de fusion |
| EP3095792A1 (fr) * | 2015-05-19 | 2016-11-23 | Klinikum rechts der Isar der Technischen Universität München | Récepteur de lymphocytes t avec une spécificité pour le peptide de myéloperoxydase et leurs utilisations |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| US10159726B2 (en) | 2015-08-28 | 2018-12-25 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| WO2017059900A1 (fr) | 2015-10-07 | 2017-04-13 | Biontech Cell & Gene Therapies Gmbh | Récepteurs antigéniques chimériques et leurs utilisations |
| WO2017060201A1 (fr) | 2015-10-09 | 2017-04-13 | Immatics Biotechnologies Gmbh | Anticorps spécifiques anti-wt1-hla |
| IL295398A (en) | 2015-10-23 | 2022-10-01 | Eureka Therapeutics Inc | Antibody/t-cell receptor chimera structures and their uses |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| US11034767B2 (en) | 2016-04-15 | 2021-06-15 | Trustees Of Dartmouth College | High affinity B7-H6 antibodies and antibody fragments |
| EP3472208B9 (fr) | 2016-06-17 | 2023-10-04 | Medigene Immunotherapies GmbH | Récepteurs de lymphocytes t et leurs utilisations |
| CN109643503A (zh) | 2016-06-27 | 2019-04-16 | 宝洁公司 | 由口腔护理产品评估牙齿过敏处理的设备和方法 |
| CA3032498A1 (fr) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions et methodes de reprogrammation de tcr en utilisant des proteines de fusion |
| EP3494984A4 (fr) | 2016-08-05 | 2020-07-22 | Tohoku University | Traitement et diagnostic du cancer ou de maladies infectieuses à l'aide du mécanisme de reconnaissance du récepteur des cellules t |
| EP3512875A2 (fr) | 2016-09-15 | 2019-07-24 | Quadrucept Bio Limited | Multimères, tétramères et octamères |
| CN106831996B (zh) * | 2017-03-31 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 具有cd3e和/或her2靶向功能的双特异性抗体及其用途 |
| EP3630811A1 (fr) | 2017-06-01 | 2020-04-08 | Universität Stuttgart | Hétérodimérisation de domaines ig |
| DK3428194T3 (da) * | 2017-07-14 | 2021-11-15 | Immatics Biotechnologies Gmbh | Forbedret polypeptidmolekyle med dobbelt specificitet |
| EP3680338A4 (fr) | 2017-09-08 | 2021-06-02 | Carsgen Therapeutics Co., Ltd. | Lymphocyte t génétiquement modifié et son application |
| JPWO2019151392A1 (ja) | 2018-01-31 | 2021-02-04 | 国立大学法人東北大学 | 抗原特異的ｍｈｃ発現調節法 |
| CN112424230A (zh) | 2018-05-14 | 2021-02-26 | 英美偌科有限公司 | 双功能结合多肽 |
| EA202091977A1 (ru) | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| WO2020018715A1 (fr) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Protéines de fusion à base d'échafaudage d'immunoglobuline multimère soluble et leurs utilisations |
| WO2020057610A1 (fr) | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Nouveaux complexes polypeptidiques anti-ctla-4/pd-1 bispécifiques |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| EP3999528A4 (fr) | 2019-07-15 | 2023-10-25 | Neogene Therapeutics B.V. | Procédé d'isolement de gènes de tcr |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| EP4025598A1 (fr) | 2019-09-06 | 2022-07-13 | Eli Lilly and Company | Protéines comprenant des domaines constants de récepteur de lymphocytes t |
| WO2021058807A1 (fr) | 2019-09-25 | 2021-04-01 | Universität Stuttgart | Molécules de liaison trivalentes |
| BR112022004789A2 (pt) | 2019-09-27 | 2022-06-21 | Agenus Inc | Proteínas heterodiméricas |
| JP2023502625A (ja) | 2019-11-15 | 2023-01-25 | グリットストーン バイオ インコーポレイテッド | 共有新抗原を標的にする抗原結合タンパク質 |
| WO2021099360A1 (fr) | 2019-11-18 | 2021-05-27 | Medigene Immunotherapies Gmbh | Récepteurs de prame tcr et utilisations correspondantes |
| US20230051847A1 (en) | 2019-12-17 | 2023-02-16 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| CN110964122B (zh) | 2019-12-24 | 2022-04-15 | 南京北恒生物科技有限公司 | T细胞受体融合蛋白及其用途 |
| CA3171906A1 (fr) | 2020-03-16 | 2021-09-23 | University Of Southern California | Nouveaux domaines de liaison a l'antigene et recepteurs d'antigenes synthetiques les incorporant |
| US20230130925A1 (en) | 2020-03-16 | 2023-04-27 | University Of Southern California | Methods to prevent, ameliorate and treat complications from viral infections |
| WO2021222576A1 (fr) | 2020-05-01 | 2021-11-04 | A2 Biotherapeutics, Inc. | Protéines de fusion pag1 et procédés de production et d'utilisation associés |
| AU2021289612A1 (en) | 2020-06-10 | 2023-01-19 | The University Of Melbourne | HIV-1 antibodies |
| US20230272071A1 (en) | 2020-07-27 | 2023-08-31 | Michael S. Kuhns | Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination |
| AU2021356681A1 (en) | 2020-10-09 | 2023-05-18 | Eureka Therapeutics Inc. | Compositions targeting ndc80/mhc complexes and uses thereof |
| WO2022083668A1 (fr) | 2020-10-21 | 2022-04-28 | Nanjing Legend Biotech Co., Ltd. | Utilisation d'un récepteur co-stimulateur chimérique pour la thérapie cellulaire |
| CA3167637A1 (fr) | 2020-12-21 | 2022-06-30 | Eric Escobar-Cabrera | Constructions tcr stabilisees et procede d'utilisation |
| WO2022178367A2 (fr) | 2021-02-19 | 2022-08-25 | University Of Southern California | Récepteurs d'antigènes synthétiques à chaîne unique et à chaînes multiples pour diverses cellules immunitaires |
-
2018
- 2018-07-13 DK DK18183508.3T patent/DK3428194T3/da active
- 2018-07-13 EP EP21191794.3A patent/EP3985029A1/fr active Pending
- 2018-07-13 CA CA3069610A patent/CA3069610A1/fr active Pending
- 2018-07-13 EP EP18183508.3A patent/EP3428194B1/fr active Active
- 2018-07-13 SG SG11202000025SA patent/SG11202000025SA/en unknown
- 2018-07-13 CN CN201880046726.5A patent/CN110914308A/zh active Pending
- 2018-07-13 HU HUE18183508A patent/HUE057110T2/hu unknown
- 2018-07-13 ES ES18740829T patent/ES2871146T3/es active Active
- 2018-07-13 PL PL18740829T patent/PL3652215T3/pl unknown
- 2018-07-13 RS RS20211381A patent/RS62544B1/sr unknown
- 2018-07-13 US US16/035,412 patent/US20190016802A1/en not_active Abandoned
- 2018-07-13 PE PE2020000056A patent/PE20200614A1/es unknown
- 2018-07-13 US US16/035,403 patent/US11905328B2/en active Active
- 2018-07-13 SG SG11202000027WA patent/SG11202000027WA/en unknown
- 2018-07-13 BR BR112020000762-5A patent/BR112020000762A2/pt unknown
- 2018-07-13 KR KR1020207004219A patent/KR20200026994A/ko not_active Application Discontinuation
- 2018-07-13 WO PCT/EP2018/069151 patent/WO2019012138A1/fr active Application Filing
- 2018-07-13 EP EP18740829.9A patent/EP3652215B1/fr active Active
- 2018-07-13 DK DK18740829.9T patent/DK3652215T3/da active
- 2018-07-13 RS RS20210561A patent/RS61817B1/sr unknown
- 2018-07-13 HR HRP20211744TT patent/HRP20211744T1/hr unknown
- 2018-07-13 PT PT187408299T patent/PT3652215T/pt unknown
- 2018-07-13 WO PCT/EP2018/069157 patent/WO2019012141A1/fr unknown
- 2018-07-13 AU AU2018298884A patent/AU2018298884A1/en active Pending
- 2018-07-13 AU AU2018298881A patent/AU2018298881A1/en active Pending
- 2018-07-13 MD MDE20190844T patent/MD3428194T2/ro unknown
- 2018-07-13 BR BR112020000769-2A patent/BR112020000769A2/pt unknown
- 2018-07-13 MD MDE20200533T patent/MD3652215T2/ro unknown
- 2018-07-13 HU HUE18740829A patent/HUE054568T2/hu unknown
- 2018-07-13 CN CN201880046721.2A patent/CN110914307A/zh active Pending
- 2018-07-13 JP JP2020501174A patent/JP2020530762A/ja active Pending
- 2018-07-13 CR CR20200013A patent/CR20200013A/es unknown
- 2018-07-13 PT PT181835083T patent/PT3428194T/pt unknown
- 2018-07-13 US US16/035,420 patent/US20190016803A1/en not_active Abandoned
- 2018-07-13 KR KR1020207004221A patent/KR20200026995A/ko not_active Application Discontinuation
- 2018-07-13 MA MA46299A patent/MA46299B1/fr unknown
- 2018-07-13 CR CR20200014A patent/CR20200014A/es unknown
- 2018-07-13 PE PE2020000058A patent/PE20200615A1/es unknown
- 2018-07-13 LT LTEP18183508.3T patent/LT3428194T/lt unknown
- 2018-07-13 ES ES18183508T patent/ES2898210T3/es active Active
- 2018-07-13 PL PL18183508T patent/PL3428194T3/pl unknown
- 2018-07-13 SI SI201830285T patent/SI3652215T1/sl unknown
- 2018-07-13 US US16/035,429 patent/US20190016804A1/en not_active Abandoned
- 2018-07-13 CA CA3069842A patent/CA3069842A1/fr active Pending
- 2018-07-13 SI SI201830456T patent/SI3428194T1/sl unknown
- 2018-07-13 LT LTEP18740829.9T patent/LT3652215T/lt unknown
- 2018-07-16 TW TW110149543A patent/TWI817302B/zh active
- 2018-07-16 TW TW107124492A patent/TWI762677B/zh active
- 2018-07-17 JP JP2018134424A patent/JP6784724B2/ja active Active
-
2020
- 2020-01-14 MX MX2020011744A patent/MX2020011744A/es unknown
- 2020-01-28 CO CONC2020/0001029A patent/CO2020001029A2/es unknown
- 2020-02-10 ZA ZA2020/00842A patent/ZA202000842B/en unknown
- 2020-02-11 CO CONC2020/0001491A patent/CO2020001491A2/es unknown
-
2021
- 2021-05-06 CY CY20211100387T patent/CY1124091T1/el unknown
- 2021-11-01 CY CY20211100934T patent/CY1124835T1/el unknown
-
2022
- 2022-03-03 US US17/686,358 patent/US20220185888A1/en active Pending
- 2022-03-12 US US17/693,323 patent/US20220195044A1/en not_active Abandoned
-
2023
- 2023-05-22 JP JP2023083663A patent/JP2023103451A/ja active Pending
- 2023-06-08 US US18/331,556 patent/US20230348598A1/en active Pending
- 2023-11-24 JP JP2023198791A patent/JP2024023385A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202000842B (en) | Improved dual specificity polypeptide molecule | |
| EP3194980A4 (fr) | Séquençage amélioré des peptides d'une seule molécule | |
| IL275298A (en) | Mitochondria-targeted peptides | |
| HK1254601A1 (zh) | 新型肽 | |
| GB201508337D0 (en) | Novel peptides | |
| PL3661983T3 (pl) | Kompozycja podwójnego katalizatora | |
| EP3302468A4 (fr) | Analogues à petites molécules du peptide de liaison nemo | |
| SG11202005653RA (en) | Novel peptide | |
| EP3377633C0 (fr) | Production de protéines recombinantes | |
| EP3269808A4 (fr) | Bêta-fructofuranosidase améliorée | |
| GB201719557D0 (en) | Polypeptide | |
| EP3309169A4 (fr) | Anticorps se liant spécifiquement à des peptides dérivés de la vimentine isolés ou fragment de liaison du peptide | |
| GB201506316D0 (en) | Novel peptide | |
| GB201700557D0 (en) | Novel peptides | |
| IL271404A (en) | Strains for improved protein expression | |
| ZA202000636B (en) | Improved dual specificity polypeptide molecule | |
| PL3710469T3 (pl) | Polipeptydy o ulepszonej swoistości transportu arabinozy | |
| GB201721387D0 (en) | Tumstatin assay | |
| GB201715378D0 (en) | Peptides | |
| GB201715379D0 (en) | Peptides | |
| GB201708471D0 (en) | Polypeptide | |
| GB201620022D0 (en) | Novel peptide | |
| GB201711620D0 (en) | Peptides | |
| GB201707837D0 (en) | Peptides | |
| GB201506360D0 (en) | Novel peptide |